[Therapy with H2 receptor antagonists in childhood. Use of ranitidine in duodenal and gastric ulcer and reflux esophagitis].
OBJECTIVE
Representation of common characteristics and peculiarities of the treatment with H2-receptor antagonists of duodenal and gastric ulcer and gastro-esophageal reflux in childhood in comparison with adults, taking ranitidine as an example.


RESULTS
In the treatment of primary and chronic duodenal and gastric ulcers, ranitidine at doses of up to 10 mg/kg/day, given in two fractions (up to 300 mg daily) is a proven form of therapy. The endoscopically confirmed healing rates after 6 to 8 weeks of acute treatment vary between 80 and 100%. The recurrence rate in children with duodenal ulcer is high, so that long-term treatment with 4 to 5 mg/kg/day (evening dose) is added. Following a recurrent ulcer, treatment should be continued for one to two years. Ranitidine has been used with success for the treatment of gastroesophageal reflux. Shorter intervals between administrations (3 times a day) with a total dose of up to 10 mg/kg/day are to be recommended. More experience is required in this area. At therapeutic doses, ranitidine shows hardly any side effects in children, even with long-term treatment, and can be considered to be very well tolerated by this age group, including babies.
Bender
S W
SW
Fachbereich Kinderheilkunde, Deutsche Klinik für Diagnostik, Wiesbaden.
D000284:Administration, Oral; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy*; D004942:Esophagitis, Peptic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008657:Metabolic Clearance Rate; D011899:Ranitidine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000097:blood / Q000188:drug therapy*
D011899:Ranitidine
Therapie mit H2-Rezeptor-Antagonisten im Kindesalter. Einsatz von Ranitidin bei Ulcus duodeni, ventriculi und Refluxösophagitis.